iBET & GenIbet are now exhibiting at CPhI North America in Philadelphia.
Seven national pharmaceutical companies, through PharmaPortugal, were present for the first time at the CPhI North America 2018 - International Pharmaceutical Industry Convention, which ran from April 24 to 26 in Philadelphia, USA.
The 2018 edition of the event has an institutional stand of PharmaPortugal, shared by Medinfar, Basi, Azevedos and iBET/Genibet. Also the companies BIAL, Bluepharma and Sidefarma were also present at the event.
Internationalization and exporting have been two of the major challenges of the national pharmaceuticals industry in recent years. In this sense, the US is a priority market, because it is the largest market in the world, with enormous potential and with the particularity of, under the Mutual Recognition Agreement (MRA) signed between the United States of America and the United States of America. European Union, to allow the acceptance of the European Good Manufacturing Practices (GMPs) by the FDA, starting in 2019.
With more than 630 exhibitors and 43 countries represented, CPhI North America is an excellent platform to promote the internationalization of Portuguese companies, allowing them to disseminate their technological skills and their export capacity, as well as to contact directly with potential clients. During the event, the PharmaPortugal stand was visited by a Portuguese delegation composed by the Secretary of State for Internationalization, Eurico Brilhante Dias, the President of INFARMED, Maria do Céu Machado, the President of APIFARMA, João Almeida Lopes, the President of the Board of AICEP Portugal, among many other guests.
PharmaPortugal is the result of a partnership between the companies of the Portuguese Pharmaceutical Industry associated with APIFARMA, INFARMED, I.P. and AICEP. The main objectives of the partnership are to publicize the innovation and research capacity of the national pharmaceutical companies, convey their image of European quality in the world and foster cooperation between pharmaceutical companies in Portugal and abroad, thus encouraging the export of products and technologically advanced services.